|
JP5006651B2
(ja)
|
2003-12-05 |
2012-08-22 |
ブリストル−マイヤーズ スクウィブ カンパニー |
２型血管内皮増殖因子受容体の阻害剤
|
|
EP2121743B1
(en)
|
2006-11-22 |
2015-06-03 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
|
KR20100128291A
(ko)
|
2008-02-14 |
2010-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
Ｅｇｆｒ에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
|
|
CN102099373A
(zh)
|
2008-05-22 |
2011-06-15 |
百时美施贵宝公司 |
基于纤连蛋白的多价支架结构域蛋白
|
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
|
|
ES2755398T3
(es)
*
|
2010-04-13 |
2020-04-22 |
Medimmune Llc |
Andamios multiméricos específicos de TRAIL R2
|
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
|
ES2573108T3
(es)
|
2010-05-26 |
2016-06-06 |
Bristol-Myers Squibb Company |
Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
|
|
EP2697257B1
(en)
|
2011-04-13 |
2016-10-19 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
US20140187488A1
(en)
|
2011-05-17 |
2014-07-03 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
|
EP2710382B1
(en)
|
2011-05-17 |
2017-10-18 |
Bristol-Myers Squibb Company |
Improved methods for the selection of binding proteins
|
|
DK2771022T3
(da)
|
2011-10-11 |
2020-09-28 |
Viela Bio Inc |
Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
|
|
US9522951B2
(en)
|
2011-10-31 |
2016-12-20 |
Bristol-Myers Squibb Company |
Fibronectin binding domains with reduced immunogenicity
|
|
EP2776061B1
(en)
|
2011-11-07 |
2019-08-14 |
MedImmune, LLC |
Multispecific and multivalent binding proteins and uses thereof
|
|
CN104136457A
(zh)
|
2011-11-08 |
2014-11-05 |
Umc乌德勒支控股有限公司 |
包括白细胞介素10和白细胞介素4的融合蛋白
|
|
US8853154B2
(en)
|
2012-09-13 |
2014-10-07 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domain proteins that bind to myostatin
|
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
US20150361159A1
(en)
|
2013-02-01 |
2015-12-17 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
|
US10787498B2
(en)
|
2013-02-06 |
2020-09-29 |
Bristol-Myers Squibb Company |
Fibronectin type III domain proteins with enhanced solubility
|
|
US10183967B2
(en)
|
2013-02-12 |
2019-01-22 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
EP3299378B1
(en)
|
2013-02-12 |
2019-07-31 |
Bristol-Myers Squibb Company |
High ph protein refolding methods
|
|
EP2968587A2
(en)
|
2013-03-13 |
2016-01-20 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
|
SMT201700530T1
(it)
|
2013-03-14 |
2018-01-11 |
Bristol Myers Squibb Co |
Combinazione di agonista di dr5 e antagonista anti-pd-1 e metodi d'uso
|
|
US10392611B2
(en)
|
2013-05-30 |
2019-08-27 |
Duke University |
Polymer conjugates having reduced antigenicity and methods of using the same
|
|
US10364451B2
(en)
|
2013-05-30 |
2019-07-30 |
Duke University |
Polymer conjugates having reduced antigenicity and methods of using the same
|
|
CN105899226B
(zh)
|
2013-10-14 |
2020-05-12 |
詹森生物科技公司 |
半胱氨酸工程化iii型纤连蛋白域结合分子
|
|
WO2015138638A1
(en)
|
2014-03-11 |
2015-09-17 |
Theraly Pharmaceuticals, Inc. |
Long acting trail receptor agonists for treatment of autoimmune diseases
|
|
CN115322253A
(zh)
|
2014-03-20 |
2022-11-11 |
百时美施贵宝公司 |
稳定化的基于纤连蛋白的支架分子
|
|
MX378753B
(es)
|
2014-03-20 |
2025-03-10 |
Bristol Myers Squibb Co |
Dominios de fibronectina tipo iii que se unen a albúmina de suero.
|
|
WO2015148269A2
(en)
*
|
2014-03-24 |
2015-10-01 |
Medimmune, Llc |
Stabilized tnfn3 scaffold proteins
|
|
NO2776305T3
(enExample)
*
|
2014-04-23 |
2018-01-27 |
|
|
|
HK1231496A1
(zh)
*
|
2014-06-20 |
2017-12-22 |
豪夫迈．罗氏有限公司 |
基於chagasin的支架组合物、方法和应用
|
|
CA2962783A1
(en)
|
2014-10-01 |
2016-04-07 |
Medimmune, Llc |
Method of conjugating a polypeptide
|
|
EA034516B1
(ru)
|
2014-11-25 |
2020-02-14 |
Бристол-Маерс Сквибб Компани |
Способы и композиции для мечения радиоактивным изотопомf биологических препаратов
|
|
CN107428817B
(zh)
|
2015-03-12 |
2022-07-12 |
免疫医疗有限责任公司 |
纯化白蛋白融合蛋白的方法
|
|
US10385115B2
(en)
|
2015-03-26 |
2019-08-20 |
Duke University |
Fibronectin type III domain-based fusion proteins
|
|
CA2985125A1
(en)
*
|
2015-05-06 |
2016-11-10 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
|
CA2994279A1
(en)
|
2015-08-04 |
2017-02-09 |
Duke University |
Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
|
|
WO2017048709A1
(en)
|
2015-09-14 |
2017-03-23 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Generating recominant affinity reagents with arrayed targets
|
|
ES2809125T3
(es)
*
|
2015-09-23 |
2021-03-03 |
Bristol Myers Squibb Co |
Moléculas de armazón a base de fibronectina de unión a glipicano-3
|
|
WO2017053617A1
(en)
|
2015-09-23 |
2017-03-30 |
Bristol-Myers Squibb Company |
Fast-off rate serum albumin binding fibronectin type iii domains
|
|
CN108699110B
(zh)
|
2015-10-23 |
2023-04-28 |
特温特大学 |
整合素结合肽及其用途
|
|
JP6797203B2
(ja)
|
2015-12-17 |
2020-12-09 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
デスレセプターアゴニストによる全身性硬化症の改善
|
|
US11752213B2
(en)
|
2015-12-21 |
2023-09-12 |
Duke University |
Surfaces having reduced non-specific binding and antigenicity
|
|
KR102508650B1
(ko)
|
2016-04-07 |
2023-03-13 |
더 존스 홉킨스 유니버시티 |
사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
|
|
IL321475A
(en)
|
2016-05-06 |
2025-08-01 |
Medimmune Llc |
Bispecific binding proteins and their uses
|
|
CN105802970A
(zh)
*
|
2016-05-30 |
2016-07-27 |
东北师范大学 |
靶向沉默Gβ1的shRNA
|
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
|
WO2017210476A1
(en)
|
2016-06-01 |
2017-12-07 |
Duke University |
Nonfouling biosensors
|
|
JP2019527540A
(ja)
|
2016-06-21 |
2019-10-03 |
ヤンセン バイオテツク，インコーポレーテツド |
システイン操作フィブロネクチンｉｉｉ型ドメイン結合分子
|
|
WO2018053201A1
(en)
|
2016-09-14 |
2018-03-22 |
Duke University |
Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
|
|
JP2020500150A
(ja)
|
2016-09-23 |
2020-01-09 |
デューク ユニバーシティ |
下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
|
|
EP3554535A4
(en)
|
2016-12-14 |
2020-10-21 |
Janssen Biotech, Inc. |
PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
|
|
EP3554561B1
(en)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
AU2017378226A1
(en)
|
2016-12-14 |
2019-06-20 |
Janssen Biotech, Inc. |
CD8A-binding fibronectin type III domains
|
|
US11648200B2
(en)
|
2017-01-12 |
2023-05-16 |
Duke University |
Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
|
|
US10787499B2
(en)
*
|
2017-02-13 |
2020-09-29 |
Regents Of The University Of Minnesota |
EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof
|
|
WO2018213320A1
(en)
|
2017-05-15 |
2018-11-22 |
Duke University |
Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
|
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
|
US11680083B2
(en)
|
2017-06-30 |
2023-06-20 |
Duke University |
Order and disorder as a design principle for stimuli-responsive biopolymer networks
|
|
WO2019147954A1
(en)
|
2018-01-26 |
2019-08-01 |
Duke University |
Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
|
|
US11491206B1
(en)
|
2018-02-13 |
2022-11-08 |
Duke University |
Compositions and methods for the treatment of trail-resistant cancer
|
|
WO2019165017A1
(en)
|
2018-02-23 |
2019-08-29 |
The University Of Chicago |
Methods and composition involving thermophilic fibronectin type iii (fn3) monobodies
|
|
US12257308B2
(en)
|
2018-04-30 |
2025-03-25 |
Duke University |
Stimuli-responsive PEG-like polymer-based drug delivery platform
|
|
KR20250151605A
(ko)
|
2018-06-01 |
2025-10-21 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
CN110724198B
(zh)
*
|
2018-07-17 |
2023-05-26 |
上海一宸医药科技有限公司 |
长效纤连蛋白iii型结构域融合蛋白
|
|
US11649275B2
(en)
|
2018-08-02 |
2023-05-16 |
Duke University |
Dual agonist fusion proteins
|
|
EP3715376A1
(en)
|
2019-03-23 |
2020-09-30 |
Ablevia biotech GmbH |
Compound for the prevention or treatment of myasthenia gravis
|
|
US11986536B2
(en)
|
2019-03-23 |
2024-05-21 |
Ablevia Biotech Gmbh |
Compound for the sequestration of undesirable antibodies in a patient
|
|
EP3715374A1
(en)
|
2019-03-23 |
2020-09-30 |
Ablevia biotech GmbH |
Compound for the sequestration of undesirable antibodies in a patient
|
|
CN114144194B
(zh)
|
2019-04-19 |
2025-03-14 |
斯纳凯恩制药私人有限责任公司 |
一种包含il13的融合蛋白
|
|
US12037378B2
(en)
|
2019-05-21 |
2024-07-16 |
Novartis Ag |
Variant CD58 domains and uses thereof
|
|
KR20220010743A
(ko)
|
2019-05-21 |
2022-01-26 |
노파르티스 아게 |
Bcma에 대한 삼중특이적 결합 분자 및 이의 용도
|
|
TWI905099B
(zh)
|
2019-05-21 |
2025-11-21 |
瑞士商諾華公司 |
Cd19 結合分子及其用途
|
|
US11512314B2
(en)
|
2019-07-12 |
2022-11-29 |
Duke University |
Amphiphilic polynucleotides
|
|
JP7772687B2
(ja)
|
2019-07-15 |
2025-11-18 |
メディミューン リミテッド |
タンパク質二量体化の三分子システム及び使用方法
|
|
WO2021076574A2
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Fn3 domain-sirna conjugates and uses thereof
|
|
EP4045061A4
(en)
|
2019-10-14 |
2024-04-17 |
ARO Biotherapeutics Company |
CD71-BINDING FIBRONECTIN TYPE III DOMAINS
|
|
US12491255B2
(en)
|
2019-10-14 |
2025-12-09 |
Aro Biotherapeutics Company |
EPCAM binding fibronectin type III domains
|
|
CN111217903B
(zh)
*
|
2020-02-25 |
2022-11-15 |
芜湖天明生物技术有限公司 |
一种重组人纤连蛋白ⅲ1-c及其制备方法和应用
|
|
EP4110407A1
(en)
|
2020-02-28 |
2023-01-04 |
Bristol-Myers Squibb Company |
Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
|
|
CN116249549A
(zh)
|
2020-03-27 |
2023-06-09 |
诺华股份有限公司 |
用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
|
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
|
CN111944204B
(zh)
*
|
2020-07-24 |
2022-03-08 |
南京理工大学 |
一种Fe3O4磁性细菌纤维素及其制备方法
|
|
MX2023003376A
(es)
|
2020-09-23 |
2023-03-31 |
Ablevia Biotech Gmbh |
Compuesto para la prevencion o el tratamiento de afecciones mediadas por autoanticuerpos.
|
|
AU2021347582A1
(en)
|
2020-09-23 |
2023-05-18 |
Ablevia Biotech Gmbh |
Compound for increasing the efficacy of factor viii replacement therapy
|
|
EP4217006A1
(en)
|
2020-09-23 |
2023-08-02 |
Ablevia biotech GmbH |
Compound for increasing efficacy of viral vectors
|
|
TW202228784A
(zh)
|
2020-09-23 |
2022-08-01 |
奧地利商艾柏力維亞生技有限公司 |
用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
|
|
EP4216990A1
(en)
|
2020-09-23 |
2023-08-02 |
Ablevia biotech GmbH |
Compound for the sequestration of undesirable antibodies in a patient
|
|
WO2022063880A1
(en)
|
2020-09-24 |
2022-03-31 |
Ablevia Biotech Gmbh |
Compound for the prevention or treatment of myasthenia gravis
|
|
IL302569A
(en)
|
2020-11-06 |
2023-07-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
WO2022097061A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
CA3214552A1
(en)
|
2021-04-14 |
2022-10-20 |
Russell C. Addis |
Cd71 binding fibronectin type iii domains
|
|
KR20240031947A
(ko)
|
2021-04-14 |
2024-03-08 |
에이알오 바이오테라퓨틱스 컴패니 |
Fn3 도메인-시르나 접합체 및 이의 용도
|
|
US20250213707A1
(en)
|
2022-03-24 |
2025-07-03 |
Ablevia Biotech Gmbh |
Compound for increasing efficacy of oncolytic viruses
|
|
KR102459313B1
(ko)
*
|
2022-04-11 |
2022-10-26 |
주식회사 대영방재산업 |
내구성이 개선된 소방용 수격 흡수기
|
|
WO2024261323A1
(en)
|
2023-06-23 |
2024-12-26 |
Astrazeneca Ab |
Molecular switches
|
|
WO2025125630A1
(en)
|
2023-12-15 |
2025-06-19 |
Medimmune Limited |
Method for bioprotac design
|